Welcome to our dedicated page for Omnicell news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell stock.
Omnicell Inc. (OMCL) is a pioneering company that has been enhancing efficiencies in healthcare since 1992. As a leading supplier of comprehensive automation and business analytics software, Omnicell focuses on patient-centric medication and supply management across the entire healthcare continuum. This includes acute care hospital settings, post-acute skilled nursing and long-term care facilities, as well as home care settings.
Omnicell's automated hardware/software systems for medication dispensing provide seamless solutions from the point of hospital entry to the central pharmacy, nursing units, operating rooms, and patient bedsides. Their supply management systems are designed to promote cost control, ensure charge capture for payer reimbursement, and facilitate efficient inventory management and reordering.
Omnicell's range of products includes high-security, closed-cabinet systems, open-shelf systems, and combination systems that are used in nursing units, cath labs, and operating rooms. These solutions empower pharmacists and nurses to concentrate on patient care rather than administrative tasks, driving improved clinical, operational, and financial outcomes across diverse care settings. With over 3,200 customers worldwide, Omnicell continues to be a trusted partner in the healthcare sector.
In recent years, Omnicell has made significant strides in advancing their technology and expanding their service offerings. Their commitment to innovation is evident in the development of new products and partnerships that aim to further streamline medication management processes. Financially, the company generates the majority of its revenue in the United States, reflecting a strong market presence and consistent performance.
Omnicell (NASDAQ:OMCL) has announced a definitive agreement to acquire FDS Amplicare for $177 million. This acquisition aims to enhance Omnicell's EnlivenHealth division by integrating a suite of financial management, analytics, and population health solutions. The deal is anticipated to broaden Omnicell’s service offerings, allowing pharmacies to improve patient outcomes and expand clinical services. The acquisition, subject to regulatory approvals, is expected to close in the second half of 2021 and will be immediately accretive to Omnicell's non-GAAP earnings.
Omnicell has expanded its Board of Directors from 9 to 10 members with the appointment of Edward P. Bousa as an independent director. Mr. Bousa, a former executive at Wellington Management Company, brings nearly 40 years of asset management experience, including significant expertise in healthcare investments. His addition is part of Omnicell's strategy to refresh its board, enhancing its governance capabilities with a focus on improving health outcomes and operational efficiencies in medication management. The board now features 8 independent directors.
Omnicell, Inc. (Nasdaq: OMCL) is set to release its financial results for Q2 2021 before the market opens on July 29, 2021. A conference call to discuss these results will follow at 8:30 a.m. ET. The company's solutions aim to enhance medication management across healthcare systems, utilized by over 7,000 facilities globally. Omnicell focuses on improving patient outcomes and reducing costs through automation and analytics, benefiting over 50,000 pharmacies in North America and the UK. Investors can access the call via phone or the company’s investor relations website.
Omnicell has partnered with Chartwell Pennsylvania to implement its IVX Workflow sterile compounding technology for managing chemotherapy drug preparations. This collaboration aims to enhance safety and accuracy in medication management, utilizing gravimetric verification and barcode scanning. The system facilitates direct orders from clinical pharmacists to cleanrooms and is set for expansion to all home infusion therapies. This partnership underscores Omnicell's commitment to improving clinical outcomes and operational efficiency in pharmacy care delivery.
Omnicell, Inc. (Nasdaq: OMCL) has secured a multi-year agreement with Scripps Health to enhance pharmacy supply chain management across its San Diego network. The partnership includes the implementation of Omnicell's XT Automated Dispensing Systems and the cloud-based intelligence service, Omnicell One™. These technologies aim to improve medication management workflows, control costs, and reduce waste. Omnicell's solutions reflect a commitment to transforming the pharmacy care delivery model, positioning the company as a leader in the Autonomous Pharmacy movement.
Omnicell, a leader in medication management solutions, reported first quarter 2021 revenues of $251.8 million, a 9.6% increase year-over-year. GAAP net income was $14.1 million, or $0.30 per diluted share, up from $11.3 million in Q1 2020. Non-GAAP net income rose to $37.5 million, or $0.83 per diluted share. The company projects Q2 2021 revenues between $265 million and $270 million.
For the full year, total revenues are expected between $1.085 billion and $1.105 billion.
Omnicell, Inc. (Nasdaq: OMCL) announced a partnership between its EnlivenHealth™ division and Twilio to enhance patient engagement solutions for retail pharmacies. This collaboration aims to integrate Twilio's cloud communication technology, optimizing workflows while maintaining personal interactions. EnlivenHealth's solutions, deployed in over 30,000 pharmacies, will now include advanced features like personalized communications, SMS, and mobile apps. This partnership is part of Omnicell's vision to advance the Autonomous Pharmacy Model, improving patient outcomes and business performance for health providers.
Omnicell (Nasdaq:OMCL) has announced that Aultman Health Foundation will implement its cloud-based medication management solutions to improve safety and efficiency in central pharmacy and point-of-care settings. This partnership aims to streamline medication processes using technology such as the Central Pharmacy Dispensing Service, which combines robotic dispensing and certified technicians. The initiative aligns with Omnicell’s vision of the Autonomous Pharmacy, intended to reduce medication errors and enhance patient care quality.
Omnicell, Inc. (NASDAQ:OMCL) will announce its Q1 2021 financial results on April 29, 2021, following market close. A conference call and webcast will be held at 4:30 p.m. ET the same day to discuss the results. Interested parties can participate by calling (855) 451-1210 in the U.S. or (236) 714-3867 internationally. Over 7,000 facilities globally utilize Omnicell's solutions, significantly enhancing operational efficiency and patient safety.
Omnicell, Inc. (Nasdaq:OMCL) reports ongoing growth in its cloud-based solutions and technology-enabled services, aligning with its Autonomous Pharmacy vision. The Christ Hospital Health Network is adopting Omnicell's Central Pharmacy Dispensing Service, automating workflows and enhancing operational efficiency. This shift targets the high error rate in manual pharmacy processes and aims to free pharmacists from non-clinical duties, improving patient care. Nearly 50% of the top 300 U.S. health systems are partnering with Omnicell to achieve a zero-error medication management infrastructure.
FAQ
What is the current stock price of Omnicell (OMCL)?
What is the market cap of Omnicell (OMCL)?
What is Omnicell Inc. known for?
When was Omnicell Inc. founded?
What types of healthcare settings does Omnicell serve?
How do Omnicell's products benefit healthcare providers?
What kinds of products does Omnicell offer?
How many customers does Omnicell have globally?
Where does Omnicell generate most of its revenue?
What recent achievements has Omnicell made?
How do Omnicell's supply management systems aid healthcare facilities?
What is the primary goal of Omnicell's products and services?
